SecBot SecBot
PRESS-RELEASE ·Filed May 29, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

This is a routine conference update with no new data released. The next major catalyst is CHAPTER-3 topline data in Q3 2026. Monitor EAACI presentations for any incremental safety/efficacy signals, but no immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$30.16
T+0 close · May 29, 2026 · via day close
Latest settled
+23.71%
T+60 · $37.31
Vs SPY
+22.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 29 $30.16entry
  2. T+1 · 6mo ago −3.51%α −3.77% · $29.10
  3. T+5 · 6mo ago +3.08%α +5.61% · $31.09
  4. T+20 · 5mo ago +15.09%α +16.88% · $34.71
  5. T+60 · 3mo ago +23.71%α +22.52% · $37.31

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Phase 3 RAPIDe-3 on-demand HAE data and Phase 2 CHAPTER-1 OLE prophylaxis data. The event is a routine scientific conference update with no new clinical data released today; the key catalyst remains the CHAPTER-3 topline data expected in Q3 2026.

Key Facts

  • 8 abstracts accepted at EAACI 2026 (June 12-15, Istanbul), including 1 oral presentation of RAPIDe-3 Phase 3 on-demand HAE data
  • 7 additional presentations cover cardiovascular safety, biomarker assay, RAPIDe-3 patient voices, and CHAPTER-1 OLE prophylaxis results
  • CHAPTER-3 global pivotal Phase 3 study of deucrictibant XR for HAE prophylaxis ongoing; topline data expected Q3 2026
  • CREAATE Phase 3 study for AAE-C1INH (prophylactic and on-demand) also ongoing
  • No new clinical data or regulatory milestones announced in this press release

Financial Impact

No financial data disclosed; event is a scientific conference update with no revenue or cost implications

Risk Factors

  • No new clinical data released today; market may be disappointed by lack of material update
  • CHAPTER-3 topline data in Q3 2026 is binary risk for the stock
  • Competitive landscape includes existing injectable HAE therapies (Takhzyro, Firazyr) and oral competitors (Orladeyo)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303489

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026